When.com Web Search

  1. Ads

    related to: long acting and short bronchodilators

Search results

  1. Results From The WOW.Com Content Network
  2. Bronchodilator - Wikipedia

    en.wikipedia.org/wiki/Bronchodilator

    Bronchodilators are either short-acting or long-acting. Short-acting medications provide quick or "rescue" relief from acute bronchoconstriction. Long-acting bronchodilators help to control and prevent symptoms. The three types of prescription bronchodilating drugs are beta-2 adrenergic agonists (short- and long-acting), anticholinergics (short ...

  3. Beta2-adrenergic agonist - Wikipedia

    en.wikipedia.org/wiki/Beta2-adrenergic_agonist

    On 18 November 2005, the U.S. Food and Drug Administration (FDA) alerted healthcare professionals and patients that several long-acting bronchodilator medicines have been associated with possible increased risk of worsening wheezing in some people, and requested that manufacturers update warnings in their existing product labeling.

  4. Discovery and development of beta2 agonists - Wikipedia

    en.wikipedia.org/wiki/Discovery_and_development...

    Short-acting β 2-agonists are used to treat exercise-induced asthma, [7] and for asthma patients to get a quick relief of symptoms. They are taken 10–15 minutes before exercise. The bronchodilation begins few minutes after inhalation of short-acting β 2-agonists and lasts from 4 to 8 hours.

  5. Formoterol - Wikipedia

    en.wikipedia.org/wiki/Formoterol

    Formoterol, also known as eformoterol, is a long-acting β 2 agonist (LABA) used as a bronchodilator in the management of asthma and chronic obstructive pulmonary disease (COPD). Formoterol has an extended duration of action (up to 12 h) compared to short-acting β 2 agonists such as salbutamol (albuterol), which are effective for 4 h to 6 h.

  6. Long-acting beta-adrenoceptor agonist - Wikipedia

    en.wikipedia.org/wiki/Long-acting_beta...

    Umeclidinium bromide is a long-acting muscarinic antagonist. [14] This combination was approved by the FDA on December 18, 2013 [15] for the long-term maintenance treatment of COPD. On March 28, 2014, it was approved in European countries [16] and in Russia [17] under the same trade name.

  7. Chronic obstructive pulmonary disease - Wikipedia

    en.wikipedia.org/wiki/Chronic_obstructive...

    [6] [144] Short-acting bronchodilators have an effect for four hours and for maintenance therapy long acting bronchodilators with an effect of over twelve hours are used. In times of more severe symptoms a short acting agent may be used in combination. [6]